Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer

Cell Death and Disease

Volumn 5, Issue 2, 2014, Pages

  De Summa, S ^a   Pinto, R ^a   Pilato, B ^a   Sambiasi, D ^a   Porcelli, L ^a   Guida, G ^b   Mattioli, E ^a   Paradiso, A ^a   Merla, G ^c   Micale, L ^c   De Nittis, P ^c   Tommasi, S ^a  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

APEX1 REF1; base excision repair; familial breast cancer; miR17; PARP1; XRCC1

Indexed keywords

APURINIC ACID; BRCA1 PROTEIN; ENDONUCLEASE; MICRORNA; MICRORNA 17; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; REDOX EFFECTOR FACTOR 1; UNCLASSIFIED DRUG; XRCC1 PROTEIN;

ADULT; AGED; APYRIMIDINIC SITE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PATIENT; CLINICAL ARTICLE; EPIGENETICS; EXCISION REPAIR; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; MIDDLE AGED; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ADULT; AGED; ANIMALS; BRCA1 PROTEIN; BRCA2 PROTEIN; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DEOXYRIBONUCLEASE (PYRIMIDINE DIMER); DNA GLYCOSYLASES; DNA REPAIR; DNA-(APURINIC OR APYRIMIDINIC SITE) LYASE; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEK293 CELLS; HUMANS; MICE; MICRORNAS; MIDDLE AGED; MUTATION; PHENOTYPE; POLY(ADP-RIBOSE) POLYMERASES; TRANSFECTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896775467     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.30     Document Type: Article

References (43)

1. Bielas JH, Loeb KR, Rubin BP, True LD, Loeb LA. Human cancers express a mutator phenotype. Proc Natl Acad Sci USA 2006; 103: 18238-18242.
2. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643-649.
3. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10 799.
4. Chacon RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010 (Suppl 2): S3.
5. Walsh T, Casadei S, Coats KH, Swisher E, Stray SM, Higgins J et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006; 295: 1379-1388.
6. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011; 5: 5-23.
7. Kerr P, Ashworth A. New complexities for BRCA1 and BRCA2. Curr Biol 2001; 11: R668-R676.
8. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002; 108: 171-182.
9. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, J Qin. BASC, a super complex of BRCA1-Associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000; 14: 927-939.
10. Le Page F, Randrianarison V, Marot D, Cabannes J, Perricaudet M, Feunteun J et al. BRCA1 and BRCA2 are necessary for the transcription-coupled repair of the oxidative 8-oxoguanine lesion in human cells. Cancer Res 2000; 60: 5548-5552.
11. Zhong Q, Boyer TG, Chen PL, Lee WH. Deficient nonhomologous end-joining activity in cell-free extracts from Brca1-null fibroblasts. Cancer Res 2002; 62: 3966-3970.
12. Hartman AR, Ford JM. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat Genet 2002; 32: 180-184.
13. Saha T, Rih JK, Roy R, Ballal R, Rosen EM. Transcriptional regulation of the base excision repair pathway by BRCA1. J Biol Chem 2010; 285: 19092-19105.
14. Abbott DW, Freeman ML, Holt JT. Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst 1998; 90: 978-985.
15. Bogliolo M, Taylor RM, Caldecott KW, Frosina G. Reduced ligation during DNA base excision repair supported by BRCA2 mutant cells. Oncogene 2000; 19: 5781-5787.
16. Xu XR, Gammon MD, Zhang YJ, Bestor TH, Zeisel SH, Wetmur JG et al. BRCA1 promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat 2009; 115: 397-404.
17. Kutanzi KR, Yurchenko OV, Beland FA, Checkhun VF, Pogribny IP. MicroRNA-mediated drug resistance in breast cancer. Clin Epigenet 2011; 2: 171-185.
18. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011; 121: 2750-2767.
19. Grigoriadis A, Mackay A, Noel E, Wu PJ, Natrajan R, Frankum J et al. Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genom 2012 619.
20. Bobola MS, Blank A, Berger MS, Stevens BA, Silber Jr. Apurinic/apyrimidinic endonuclease activity is elevated in human adult gliomas. Clin Cancer Res 2001; 7 3518.
21. Thomson B, Tritt R, Davis M, Kelley MR. Histology-specific expression of a DNA repair protein in pediatric rhabdomyosarcomas. J Pediatr Hematol/Oncol 2001; 23 239.
22. Puglisi F, Aprile G, Minisini AM, Barbone F, Cataldi P, Tell G et al. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. Anticancer Res 2001; 21: 4041-4049.
23. Koukourakis MI, Giatromanolaki A, Kakolyris S, Sivridis E, Georgoulias V, Funtzilas G et al. Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/REF-1) in head-And-neck cancer is associated with resistance to chemoradiotherapy and poor outcome. Int J Radiat Oncol 2001; 50: 27-36.
24. Robertson KA, Bullock HA, Xu Y, Tritt R, Zimmerman E, Ulbright TM et al. Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation. Cancer Res 2001; 61: 2220-2225.
25. Wu HH, Chu YC, Wang L, Tsai LH, Lee MC, Chen CY et al. Cytoplasmic Ape1 expression elevated by p53 aberration may predict survival and relapse in resected non-small cell lung cancer. Ann Surg Oncol 2012; 20(Suppl 3): S336-S347.
26. Barzilay G, Walker LJ, Robson CN, Hickson ID. Site-directed mutagenesis of the human DNA repair enzyme HAP1: Identification of residues important for AP endonuclease and RNase H activity. Nucleic Acids Res 1995; 23: 1544-1550.
27. Luo M, Kelley MR. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 2004; 24: 2127-2134.
28. Fishel ML, He Y, Smith ML, Kelley MR. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res 2007; 13 267.
29. Liu L, Nakatsuru Y, Gerson SL. Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 2002; 8: 2985-2991.
30. Taverna P, Liu LL, Hwang HS, Hanson AJ, Kinsella TJ, Gerson SL. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Res-DNA Repair 2001; 485: 269-281.
31. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009; 69: 3589-3596.
32. Fong PC, Boss DS, Yap TA, Tutt A, Wu PJ, Mergui-Roelvink M et al. Inhibition of poly (ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009 123-134.
33. Chuang HC, Kapuriya N, Kulp SK, Chen CS, Shapiro CL. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells. Breast Cancer Res Treat 2012; 134: 649-659.
34. Goncalves A, Finetti P, Sabatier R, Gilabert M, Adelaide J, Borg JP et al. Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: A meta-Analysis. Breast Cancer Res Treat 2011; 127: 273-281.
35. Turner NC, Reis JS, Russell AM, Springall RJ, Ryder K, Steele D et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007; 26: 2126-2132.
36. Ladiges WC. Mouse models of XRCC1 DNA repair polymorphisms and cancer. Oncogene 2006; 25: 1612-1619.
37. Nazarkina ZK, Khodyreva SN, Marsin S, Radicella JP, Lavrik OI. Study of interaction of XRCC1 with DNA and proteins of base excision repair by photoaffinity labeling technique. Biochemistry (Moscow) 2007; 72: 878-886.
38. Weaver DA, Crawford EL, Warner KA, Elkhairi F, Khuder SA, Willey JC. ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer 2005; 4: 18.
39. Sultana R, Abdel-Fatah T, Abbotts R, Hawkes C, Albarakati N, Seedhouse C et al. Targeting XRCC1 deficiency in breast cancer for personalized therapy. Cancer Res 2013 1621-1634.
40. Wang HC, Perrault AR, Takeda Y, Qin W, Wang HY, Iliakis G. Biochemical evidence for Ku-independent backup pathways of NHEJ. Nucleic Acids Res 2003; 31: 5377-5388.
41. Dibiase SJ, Zeng ZC, Chen R, Hyslop T, Curran WJ, Iliakis G. DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res 2000; 60: 1245-1253.
42. Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M et al. Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res 2008; 644: 64-70.
43. Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 2011; 105: 372-381.